With agentic AI, the database must evolve from a passive ledger to an active reasoning engine that informs, guides, and ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
Abstract: Anomaly detection is a fundamental task in hyperspectral image (HSI) processing. However, most existing methods rely on pixel feature vectors and overlook the relational structure ...
Abstract: Correlation-diversified portfolios can be constructed by finding the maximum independent sets (MISs) in market graphs with edges corresponding to correlations between two stocks. The ...
Multi-agent explanatory AI: turns hybrid retrieval (Elasticsearch) into sourced causal chains with a graph view and LLM-backed summarization (Vertex AI / Gemini). Ships with a FastAPI backend and ...
Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...
The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.
BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter net income of $1.08 billion. On a per-share basis, the Boston-based company said it had profit of $4.20.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback